William Sheldon, DO
Interventional Cardiology · Sandusky, OHNPI 1124008941
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,565 of the $5,559 with a category attached, or 82.1%. 30 manufacturers reported payments, led by Medtronic at 42.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in OH, where the typical reported total is $4,547.
Across 204 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$888
- Johnson & Johnson$353
- E.r. Squibb & Sons, L.L.C.$271
- Amgen$210
- Shockwave Medical, Inc$181
- plus $1K from 24 others
Across 68 payments — averaging $1826.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$96K
- Sanofi US Services Inc.$15K
- AstraZeneca$14K
What the payments were for
- Consulting fees$110%
- Travel & lodging$89216%
- Food & beverage$4,56582%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $2,376 |
| Novartis | 57 | $888 |
| Johnson & Johnson | 19 | $353 |
| E.r. Squibb & Sons, L.L.C. | 24 | $271 |
| Amgen | 13 | $210 |
| Shockwave Medical, Inc | 6 | $181 |
| Abbott | 2 | $148 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Penumbra, Inc. | 1 | $104 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $87 |
| Astellas Pharma US Inc | 1 | $85 |
| Regeneron Healthcare Solutions, Inc. | 6 | $79 |
| Amarin Pharma, Inc. | 4 | $69 |
| Sanofi-aventis U.S. LLC | 5 | $67 |
| AstraZeneca | 4 | $59 |
| Lundbeck LLC | 4 | $59 |
| Thrombolex, Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $56 |
| Abiomed | 2 | $55 |
| Philips North America LLC | 2 | $37 |
| Pfizer | 3 | $37 |
| Terumo Medical Corporation | 2 | $28 |
| Inari Medical, Inc. | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Angiodynamics, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $13 |
| EKOS Corporation | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
| Z-medica, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,030
- XARELTO$245
- ONYX FRONTIER$134
- MitraClip$129
- Indigo System$104
- Onyx$102
How this compares
$5,559 in reported general payments places this provider in the 50th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 326 | $411,254 |
| EntrestoSacubitril/Valsartan | 147 | $212,836 |
| XareltoRivaroxaban | 147 | $180,756 |
| BrilintaTicagrelor | 132 | $115,423 |
| JardianceEmpagliflozin | 81 | $105,524 |
| Repatha SureclickEvolocumab | 30 | $29,837 |
| Repatha SyringeEvolocumab | 12 | $17,479 |
| Atorvastatin Calcium | 1,464 | $17,028 |
| Valsartan | 338 | $12,918 |
| Metoprolol Succinate | 629 | $8,543 |
| ClopidogrelClopidogrel Bisulfate | 573 | $6,528 |
| Carvedilol | 685 | $5,986 |
| Rosuvastatin Calcium | 248 | $5,076 |
| Nitroglycerin PatchNitroglycerin | 101 | $4,341 |
| Nitroglycerin | 208 | $4,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $411,254326 claims |
| NovartisEntresto | $888 | $212,836147 claims |
| Johnson & JohnsonXarelto | $353 | $180,756147 claims |
| AstraZenecaBrilinta | $59 | $115,423132 claims |
| Boehringer IngelheimJardiance | $56 | $105,52481 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Sandusky
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.